An updated Review on Therapeutic Potential of Entrectinib as a Promising TrK, ROS 1, and ALK Inhibitor in Solid Tumors and Lung Cancer
M. Archana
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
Mariya Palathingal
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
K. Athulya Damodharan
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
P. Ashisha
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
Nuaman, Akash Marathakam *
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
*Author to whom correspondence should be addressed.
Abstract
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gained its first worldwide approval in Japan in June 2019 for the treatment of NTRK fusion-positive, advanced or recurring solid tumours in adults and children. In august 15, 2019 drug got FDA approval for the treatment of solid tumors in adult and children aged 12 and above. This article summarizes current status of Entrectinib from ongoing clinical trails and ideal place for drug in therapy.
Keywords: Entrectinib, non-small cell lung cancer, TrkA, TrkB, TrkC, NTRK, ALK, ROS1